found that adjunctive dexamethasone, the standard of care in CNS-TB, significantly decreased CSF MMP-9 concentrations in TBM patients, but the decline in MMP-9 concentrations was not associated with improved outcome (10). The gene discussed is MMP9; the disease is meningeal tuberculosis.